Randomized, double-blind, adjuvant- and placebo-controlled, dose-escalating study to evaluate safety, tolerability, and immunogenicity of leish-111f + MPL-SE vaccine with meglumine antimoniate (Glucantime) in cutaneous leishmaniasis.

Trial Profile

Randomized, double-blind, adjuvant- and placebo-controlled, dose-escalating study to evaluate safety, tolerability, and immunogenicity of leish-111f + MPL-SE vaccine with meglumine antimoniate (Glucantime) in cutaneous leishmaniasis.

Completed
Phase of Trial: Phase I

Latest Information Update: 02 Aug 2010

At a glance

  • Drugs LEISH-F3 peptide vaccine (Primary) ; Monophosphoryl lipid A (Primary) ; ; Meglumine antimonate
  • Indications Cutaneous leishmaniasis
  • Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
  • Most Recent Events

    • 02 Aug 2010 Results reported in Vaccine.
    • 24 Mar 2009 Additional lead trial centres and investigators identified as reported by ClinicalTrials.gov.
    • 18 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top